January 2026

MSN Group is the fastest growing research-based pharmaceutical company based out of India. Founded in 2003 with a mission to make health care affordable, this Hyderabad-based venture has Fifteen API and Six finished dosage facilities established across India & USA.  The group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals to make them more accessible.

WALK IN DRIVE for Formulation Division at VIZAG 

British pharmaceutical firm AstraZeneca PLC announced on Thursday it will commit usd 15 billion (about ₹1.2 lakh crore) to expand research, development and manufacturing operations in China through 2030, underscoring the country’s growing importance in global drug innovation and production.

The investment, detailed in a company press release, aims to bolster AstraZeneca’s capabilities across the entire drug value chain from discovery and clinical development to large-scale manufacturing, particularly in cell therapies and radioconjugates, two areas of rapid scientific advance.

Alzheimer Europe today released a new report titled “The Prevalence of Dementia in Europe 2025”, projecting a substantial rise in the number of people living with dementia across the continent over the next quarter-century. The report updates prevalence figures using recent community-based studies and United Nations population projections for 2025 and 2050.